JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1083/jcb.1791rr3
The Journal of Cell Biology, Vol. 179, No. 1, 5-
The Rockefeller University Press, 0021-9525 $30.00
© LeBrasseur
This Article
Right arrow Full Text (PDF, 872K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Roundup

Apoptosis prevents osteoporosis



Figure 1
The survival of osteoclasts (top, purple) in mice lacking estrogen receptors (right) leads to loss of bone mass (bottom).

KATO/ELSEVIER

Grandmothers everywhere know well that estrogen deficits lead to osteoporosis. Now, the molecular basis for this debilitating bone loss is finally identified. Estrogen is needed to kill off bone-destroying osteoclasts, show Takashi Nakamura, Shigeaki Kato (University of Tokyo, Japan), and colleagues.

The root cause of osteoporosis has been difficult to pin down, in part because bones are not frail in female mice lacking estrogen receptors. These mice make extra androgen, which builds bone in male mice and might compensate for bone loss in the mutant females.

To avoid the androgen rise, Kato's group knocked out estrogen receptors only in mature osteoclasts, which accumulate in osteoporotic bones. These female mutants developed rickety bones due to losses within the central bone shafts.

The authors then isolated osteoclasts to determine why they are so abundant in diseased bone. Microarray analyses revealed that estrogen induced apoptotic proteins, including Fas ligand, that were not induced in the estrogen-blind osteoclasts.

Men who have estrogen receptor mutations develop osteoporosis. But male mice were not affected by the loss of estrogen receptors in osteoclasts. Perhaps the androgen-headed pathway is more dominant in mice than in humans.

Currently, potential drugs to treat osteoporosis are screened through mice whose ovaries have been removed. Screens for the induction of Fas ligand in cultures of estrogen-blind osteoclasts should be much simpler. Formula

Reference:

Nakamura, T., et al. 2007. Cell. 130:811–823.[CrossRef][Medline]



Nicole LeBrasseur

lebrasn{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 872K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents